Cheers @lastever , results have looked good, efficacy results have been on small samples so far but the Gel (R327G) for topical application looks very promising and the unusual approach to do Phase 3 and commercialise in Indonesia at the same time as TGA Phase 3 for FDA (which will take twice as long) is a sign of their confidence. It may also accelerate the interest of a major pharma company if they can show in market effectiveness. We should get some initial results around mid-way through Phase 3 that I hope will provided more clarity on degree of effectiveness and any issues impacting efficacy.

It may also help support interest in the intravenous application (R327) which is further behind in the clinic. A pharma deal to help fund clinical trials and commercialise has to be high up on their wish list, I can't see them taking any of their products to market - case in point is the partnership in Indonesia with PT Etana Biotechnologies to run the trials and I expect there are some commericalisation elements.

As you point out antibiotic resistance is a major issue from a health perspective. However it is also a problem with the business model for companies developing antibiotics/anti-infectives, because it's just not worth the cost to research and develop new antibiotics due to the short time in market they can be used before becoming ineffective. This is probably why Recce has had trouble getting interest from major pharma companies because the whole antibiotic area of medicine has been such a business disaster that no one is interested.

The game changer for R327 is that it appears to overcome resistance and that in-vitro (lab) testing shows that it doesn't build up over time, so if it is approved then it will have a long life in market and due to it's designations it has extended patents so will be covered for longer than most drugs.

So if it works and is approved, it will be a revolutionary health outcome and extraordinary commercial success. Something I am backing with our families hard earned cash.